Clinical Trial Update: A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a neoantigen-targeted ppDC vaccine for diffuse hemispheric glioma with H3 G34 mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Hemispheric Glioma H3 G34-mutant

Drugs mentioned

• Neoantigen-Targeted ppDC vaccine

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Status: ACTIVE_NOT_RECRUITING